GGrantIndex
← Leaderboards

John A Secrist

Southern Research Institute

$6,038,272
Attributed
$6,038,272
Total exposure
7
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $855.2K · FY200812
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12

Funding mix

By agency

NIH$6,038,272 · 7

By mechanism

R01$2,251,169 · 1
P01$1,523,546 · 2
U01$1,087,535 · 1
N01$778,162 · 1
U54$397,860 · 1
U19$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Southern Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Nucleoside Analog

Research focus

Nucleoside AnalogDrug Design /Synthesis /ProductionStructural BiologyAntineoplasticsCytotoxicityComputer SimulationPurinesNeoplastic CellProdrugsCooperative StudyStructurePharmaceutical PreparationsResearch PersonnelLaboratoriesAnimal ModelEnzymesDna-Directed Dna PolymeraseDesignDrug DiscoveryBaseEvaluationIn VivoCarbohydratesCell Death

Grant awards (20)

4'-Substituted nucleoside analogs as anticancer drugs$441,240
R01 · FY2012 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$441,240
R01 · FY2011 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$455,093
R01 · FY2010 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$456,229
R01 · FY2009 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$457,367
R01 · FY2008 · CA · contact PI
Drug Design and Synthesis for Orthopoxvirus Infections$397,860
U54 · FY2008 · AI · contact PI
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$289,564
U01 · FY2003 · AI
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$260,045
U01 · FY2002 · AI
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$228,401
P01 · FY2002 · CA
NUCLEOSIDES WITH ALTERED METABOLISM$228,401
P01 · FY2002 · CA
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2002 · CA
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$272,938
U01 · FY2001 · AI
NUCLEOSIDES WITH ALTERED METABOLISM$228,401
P01 · FY2001 · CA
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$228,401
P01 · FY2001 · CA
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2001 · CA
TB DRUG SCREENING:TB ANTIMICROBIAL ACQ &COORD. FACILITY$778,162
N01 · FY2000 · AI
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$304,971
P01 · FY2000 · CA
NUCLEOSIDES WITH ALTERED METABOLISM$304,971
P01 · FY2000 · CA
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$264,988
U01 · FY2000 · AI
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2000 · CA